Cagrilintide: Comprehensive Research Guide

Overview

Cagrilintide (AM833) is a long-acting amylin receptor agonist currently under investigation for weight management. Amylin is a hormone co-secreted with insulin that helps regulate food intake and glucose metabolism. Cagrilintide mimics these effects with an extended half-life.

Mechanism of Action

Amylin Receptor Agonism

• Appetite Suppression: Reduces food intake and appetite
• Gastric Emptying: Delays gastric emptying
• Satiety: Promotes feelings of fullness
• Glucose: May improve glucose control

Weight Loss

• Significant Loss: Promotes substantial weight loss
• Sustained: Long-acting formulation provides sustained effects
• Combination: Often studied in combination with semaglutide

Research Applications

Weight Management

• Obesity: Treatment of obesity
• Weight Loss: Significant weight loss in trials
• Long-term: Potential for long-term weight management
• Combination: Research into combination therapies

Dosage

• Research: 0.3-4.5 mg weekly
• Typical: 2.4-4.5 mg weekly
• Administration: Subcutaneous injection
• Frequency: Once weekly

Side Effects

• GI Effects: Nausea, vomiting, diarrhea, constipation
• Mild to Moderate: Generally mild to moderate
• Tolerance: May improve with continued use

Storage

• Temperature: 2-8°C (refrigerated)
• Do Not Freeze: Protect from freezing
• Light: Protect from light

This information is for research and educational purposes only. Cagrilintide is investigational and not approved for human use.